Skip to content
OpenCapital
Get started

NRX Pharmaceuticals, Inc. NRXP Q4 2025 Annual earnings

Reported March 23, 2026 · Before market open

Revenue$983.0KMiss by $6.5MDiluted EPS$0.19Beat by $0.28
Revenue estimate$7.5M
EPS estimate-$0.09

Next report

Aug 17, 2026 (in a month)
Revenue estimate$1.7M
EPS estimate-$0.09

Versus estimates

Revenue

Q1 2026$1.1MMiss by $18.4M
Q4 2025$983.0KMiss by $6.5M
Q3 2025$242.0KMiss by $7.3MQ1 2025$2.3MQ4 2024$4.0KMiss by $5.0M

Diluted EPS

Q1 2026-$0.04Beat by $0.01
Q4 2025$0.19Beat by $0.28
Q3 2025-$0.18Miss by $0.07Q1 2025-$0.34Miss by $0.04Q4 2024-$0.30Miss by $0.10Q3 2024-$0.15Beat by $0.66

Ask the moment NRX Pharmaceuticals, Inc. reports.

Connect your AI and ask the moment the filing drops. It reads the release, surfaces what management said, and gives you its own read.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

When did NRX Pharmaceuticals, Inc. report Q4 2025 earnings?
NRX Pharmaceuticals, Inc. (NRXP) reported Q4 2025 earnings on March 23, 2026 before market open.
What were NRX Pharmaceuticals, Inc.'s Q4 2025 revenue and EPS?
NRX Pharmaceuticals, Inc. reported revenue of $983.0K and diluted EPS of $0.19 for Q4 2025.
Did NRX Pharmaceuticals, Inc. beat estimates in Q4 2025?
Revenue missed the consensus estimate of $7.5M by $6.5M. EPS beat the consensus estimate of $-0.09 by $0.28.
How did NRX Pharmaceuticals, Inc.'s Q4 2025 results compare year-over-year?
Compared to the same quarter a year prior, revenue grew 24475.0% from $4.0K a year earlier.
Where can I find NRX Pharmaceuticals, Inc.'s Q4 2025 SEC filings?
You can read the 8-K earnings release (0001437749-26-009611) and the 10-K periodic report (0001437749-26-009418) directly on SEC EDGAR. The filing index links above go to sec.gov.